BI 1820237

DRUG3 trials

Sponsors

Boehringer Ingelheim

Conditions

HealthyObesity

Phase 1

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

CompletedNCT04903509

Boehringer IngelheimHealthy

Start: 2021-06-08End: 2022-08-26Updated: 2022-08-31

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

CompletedNCT05751226

Boehringer IngelheimHealthy, Obesity

Start: 2023-04-11End: 2024-08-01Updated: 2025-01-22

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

CompletedNCT06352424

Boehringer IngelheimObesity

Start: 2024-04-30End: 2025-02-24Updated: 2025-03-12

Related Papers

A randomized phase I study of <scp>BI</scp> 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low‐dose liraglutide in otherwise healthy men with overweight or obesity

Diabetes Obesity and Metabolism2024-10-077 citations